Eurofins announced that it has successfully completed the acquisition of a majority stake in Bio-EC, Spincontrol, and Genex, part of Bio-EC / Spincontrol Group, as part of its ambitions to further expand its global Cosmetics & Personal Care offering.
Adds Ex-vivo Objectivation & Cosmetogenomic Capabilities
The acquisition adds ex vivo objectivation and cosmetogenomic capabilities and strengthens the Eurofins Group’s ability to perform ad-hoc clinical efficacy studies, emotion studies, and image analysis.
By joining forces, Eurofins Cosmetics & Personal Care (C&PC) and Bio-EC, Spincontrol, and Genex will leverage their respective expertise and capabilities to provide creative, unique, and integrated solutions for cosmetics, food supplements, and medical devices.
The French-based companies are headquartered in Paris and Tours, with three facilities in France and Canada, and employ 58 people.
With 24 years of experience, Bio-EC brings innovative capabilities to Eurofins, with a strong position in ex vivo models and mechanisms and in vitro toxicology services, as well as new clinical facilities in Paris and unique expertise with its own in-house RAMAN. With the most sophisticated research and development capabilities, and equipment, Bio-EC is involved in several research and innovation projects and channels its expertise into offering new models and methods each year.
One of the industry’s most experienced and influential companies in clinical efficacy studies, Spincontrol France and Spincontrol Canada support Eurofins Cosmetics & Personal Care’s ambition to consolidate its portfolio and capture the value it brings to its customers. Well-known in the market, thanks to their 31 years of experience, Spincontrol will allow Eurofins C&PC to expand upon existing clinical capabilities, ad-hoc testing protocols and emotion studies, open access to in-house image analysis, and new shooting technologies, and bring its companies closer to local and regional customers in France and Canada.
Genex's expertise in cosmetogenomics will support Eurofins C&PC in offering new gene expression monitoring to its customers, to comprehensively identify product effects and reveal new targets and mechanisms.
Source: Eurofins